
    
      This is a dose escalation study to evaluate the safety, immunogenicity, and efficacy of 3
      doses of HSV plasmid DNA (pDNA) vaccines formulated with VaxfectinÂ® in subjects with a
      minimum of 1 year of reported history of genital herpes, and either 2 to 9 recurrences within
      the year prior to screening, or 2 to 9 recurrences per year prior to starting suppressive
      therapy.
    
  